Eris Lifesciences launches affordable semaglutide

Indian pharmaceutical company Eris Lifesciences has introduced a generic version of semaglutide, a popular diabetes and weight loss medication. This new offering is priced at a significantly lower cost of $13.8 per month, making it more accessible to a wider patient population in India. The move aims to address the growing demand for effective treatments for type 2 diabetes and obesity, while also challenging the market dominance of existing high-cost alternatives. This launch is expected to increase competition and potentially drive down prices further in the Indian market.